Skip to content
Not evaluated by SAHPRA · Research & educational information only · Nothing on this site is for sale · Not medical advice · Consult a healthcare professional
Not evaluated by SAHPRA. Research & educational information only — nothing is for sale; not intended to diagnose, treat, cure or prevent any disease.
← Back to catalogue
Weight LossPeptide vialGLP-1GIPWeight Loss

UPA Tirzepatide

Dual GIP + GLP-1 agonist. Next-generation weight management.

Format
Peptide vial
Strength / pack
30 mg vial
Category
Weight Loss
Dual mechanismHits both GIP and GLP-1 receptors for stronger metabolic effect.
Greater fat lossClinical trials show larger weight reduction vs. single-pathway GLP-1s.
Blood sugar controlPowerful insulin sensitization.
Appetite regulationSubstantial reduction in hunger and food cravings.
Tirzepatide is a dual agonist binding both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors. This dual action drives larger improvements in glucose regulation and weight than GLP-1 mono-agonism.
Publisher
Elegant Slimming · Mokopane, Limpopo, South Africa
Research library · nothing on this site is for sale.
Regulatory
This compound has not been evaluated by the South African Health Products Regulatory Authority (SAHPRA).
For information purposes only — not intended to diagnose, treat, cure or prevent any disease.